AstraZeneca (AZN.US) releases groundbreaking Phase III clinical results for new ADC drug "Datuximab"

According to the Wisdom Finance APP, AstraZeneca (AZN.US) recently announced that the positive results of the DESTINY-Breast09 Phase 3 study showed that as first-line treatment for HER2-positive metastatic breast cancer patients, trastuzumab deruxtecan in combination with pertuzumab demonstrated a significantly higher and clinically meaningful improvement in progression-free survival (PFS) compared to the current first-line standard treatment regimen THP (taxane-based drugs in combination with pertuzumab and trastuzumab). The results of the DESTINY-Breast09 Phase 3 study will be presented in a special oral presentation form at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.